A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT05650632 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

210

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Etentamig (ABBV-383)

Sponsor

AbbVie